ArticleHaematologica2012
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.
Article in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Utilization of kinase inhibitors as novel therapeutic drug targets: A review.Oncology research · 2022Review
- Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer.Molecular cancer therapeutics · 2020Review
- Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.The American journal of case reports · 2017Review
- Cell biology: a key driver of therapeutic innovation.The Journal of cell biology · 2012Article
- The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Cancer research · 2012Review
- Structure, regulation, signaling, and targeting of abl kinases in cancer.Genes & cancer · 2012Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.